Have a feature idea you'd love to see implemented?
Let us know!
EBAC European Biotech Acquisition Corp
Price (delayed)
$11.19
Market cap
$183.5M
P/E Ratio
559.5
Dividend/share
N/A
EPS
$0.02
Enterprise value
$183.19M
Highlights
The quick ratio has soared by 95% from the previous quarter but it has plunged by 77% YoY
EBAC's price to earnings (P/E) is 151% more than its last 4 quarters average of 223.2
The company's EPS has shrunk by 82% YoY and by 50% QoQ
Key stats
What are the main financial stats of EBAC
Market
Valuations
Earnings
Shares outstanding
16.4M
Market cap
$183.5M
Enterprise value
$183.19M
Price to earnings (P/E)
559.5
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
534.25
EV/EBITDA
534.25
EV/Sales
N/A
Revenue
$0
EBIT
$342,895
EBITDA
$342,895
Free cash flow
-$514,792
Per share
Balance sheet
Liquidity
EPS
$0.02
Free cash flow per share
-$0.03
Book value per share
-$0.49
Revenue per share
$0
TBVPS
$7.91
Total assets
$129.75M
Total liabilities
$8.55M
Debt
$0
Equity
-$8.06M
Working capital
-$438,931
Debt to equity
0
Current ratio
0.45
Quick ratio
0.39
Net debt/EBITDA
-0.9
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
0.3%
Return on equity
N/A
Return on invested capital
0.3%
Return on capital employed
0.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EBAC stock price
How has the European Biotech Acquisition stock price performed over time
Intraday
-4.44%
1 week
13.6%
1 month
10.14%
1 year
15.01%
YTD
10.79%
QTD
10.79%
Financial performance
How have European Biotech Acquisition's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$2.82M
Net income
$342,895
Gross margin
N/A
Net margin
N/A
The operating income has plunged by 156% YoY and by 29% from the previous quarter
European Biotech Acquisition's net income has shrunk by 77% YoY and by 60% QoQ
Growth
What is European Biotech Acquisition's growth rate over time
Valuation
What is European Biotech Acquisition stock price valuation
P/E
559.5
P/B
N/A
P/S
N/A
EV/EBIT
534.25
EV/EBITDA
534.25
EV/Sales
N/A
EBAC's price to earnings (P/E) is 151% more than its last 4 quarters average of 223.2
The company's EPS has shrunk by 82% YoY and by 50% QoQ
EBAC's equity is down by 33% since the previous quarter and by 21% year-on-year
Efficiency
How efficient is European Biotech Acquisition business performance
The ROA has plunged by 75% YoY and by 57% from the previous quarter
The return on invested capital has dropped by 75% year-on-year and by 57% since the previous quarter
Dividends
What is EBAC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EBAC.
Financial health
How did European Biotech Acquisition financials performed over time
The quick ratio has soared by 95% from the previous quarter but it has plunged by 77% YoY
The company's current ratio has shrunk by 75% YoY but it has surged by 61% QoQ
EBAC's debt is 100% more than its equity
EBAC's equity is down by 33% since the previous quarter and by 21% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.